These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23014660)

  • 1. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
    Steinman RA; Brufsky AM; Oesterreich S
    Breast Cancer Res; 2012 Sep; 14(5):213. PubMed ID: 23014660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
    Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
    Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
    J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and breast cancer prevention.
    Chlebowski RT; Col N
    Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone-modifying Agents (BMAs) in Breast Cancer.
    Shapiro CL
    Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
    Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
    Clin Breast Cancer; 2010 Dec; 10(6):471-6. PubMed ID: 21147691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.
    Hadji P; Coleman R; Gnant M; Green J
    Ann Oncol; 2012 Nov; 23(11):2782-2790. PubMed ID: 22730099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
    Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
    Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches.
    Soki FN; Li X; Berry J; Koh A; Sinder BP; Qian X; Kozloff KM; Taichman RS; McCauley LK
    J Cell Biochem; 2013 Jan; 114(1):67-78. PubMed ID: 22833499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid for adjuvant use in patients with breast cancer.
    Ressler S; Mlineritsch B; Greil R
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
    Hershman DL; McMahon DJ; Crew KD; Shao T; Cremers S; Brafman L; Awad D; Shane E
    J Clin Endocrinol Metab; 2010 Feb; 95(2):559-66. PubMed ID: 20022990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.